Why the study?
Do Factor Xa inhibitors prevent cerebral or systemic embolism compared to vitamin K antagonists in people with atrial fibrillation?
Do Factor Xa inhibitors prevent cerebral or systemic embolism compared to vitamin K antagonists in people with atrial fibrillation?
This is an update of a 2013 Cochrane review evaluating the efficacy of Factor Xa inhibitors versus vitamin K antagonists for stroke and systemic embolism prevention in atrial fibrillation.
Supports preferring factor Xa inhibitors over vitamin K antagonists for atrial fibrillation stroke prevention; confirms and extends 2013 review findings.
Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in treatment guidelines for preventing stroke and systemic embolic events in people with atrial fibrillation (AF). This is an update of a Cochrane review previously published in 2013.
No takes yet. Share an insight, caveat, or question.
Slot et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: